{
    "root": "34f44991-fc66-a383-e063-6294a90a24cf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SODIUM POLYSTYRENE SULFONATE",
    "value": "20250512",
    "ingredients": [
        {
            "name": "SODIUM POLYSTYRENE SULFONATE",
            "code": "1699G8679Z",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_33543"
        }
    ],
    "indications": {
        "text": "sodium polystyrene sulfonate suspension indicated treatment hyperkalemia . limitation : sodium polystyrene sulfonate suspension used emergency treatment life-threatening hyperkalemia delayed onset action [ pharmacology ( 12.2 ) ]",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "oral : average total daily adult dose sodium polystyrene sulfonate 15 g 60 g , administered 15-g dose ( four level teaspoons ) , one four times daily ( 2.1 ) . rectal : average adult dose 30 g 50 g every six hours ( 2.1 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sodium polystyrene sulfonate suspension available golden brown , finely ground powder . ndc : 72162-1230-02 : jars 1 pound ( 454 g ) . ndc : 72162-1230-07 : bottles 15 g , store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0-30\u00b0c ( 59\u00b0-86\u00b0f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "sodium polystyrene sulfonate contraindicated patients following conditions : hypersensitivity polystyrene sulfonate resins obstructive bowel disease neonates reduced gut motility",
    "indications_original": "Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia.\n                  \n                     Limitation of Use:\n\n \n                  Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see\n \n  \n                        Clinical Pharmacology (12.2)\n                     ]",
    "contraindications_original": "Oral : The average total daily adult dose of sodium polystyrene sulfonate is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily ( 2.1 ). Rectal : The average adult dose is 30 g to 50 g every six hours ( 2.1 ).",
    "warningsAndPrecautions_original": "Sodium polystyrene sulfonate for suspension is available as a golden brown, finely ground powder.\n                  NDC: 72162-1230-02: in jars of 1 pound (454 g).\n                  NDC: 72162-1230-07: in bottles of 15 g,\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0-30\u00b0C (59\u00b0-86\u00b0F) [see USP Controlled Room Temperature].\n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "Sodium polystyrene sulfonate is contraindicated in patients with the following conditions:\n                  \n                     Hypersensitivity to polystyrene sulfonate resins\n                     Obstructive bowel disease\n                     Neonates with reduced gut motility",
    "drug": [
        {
            "name": "SODIUM POLYSTYRENE SULFONATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_33543"
        }
    ]
}